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Abstract
It has long been recognized that generalized deficits in cognitive ability represent a core 
component of schizophrenia, evident prior to full illness onset and independent of medication. The 
possibility of genetic overlap between risk for schizophrenia and cognitive phenotypes has been 
suggested by the presence of cognitive deficits in first-degree relatives of patients with 
schizophrenia; however, until recently, molecular genetic approaches to test this overlap have 
been lacking. Within the last few years, large-scale genome-wide association studies (GWAS) of 
schizophrenia have demonstrated that a substantial proportion of the heritability of the disorder is 
explained by a polygenic component consisting of many common SNPs of extremely small effect. 
Similar results have been reported in GWAS of general cognitive ability. The primary aim of the 
present study is to provide the first molecular genetic test of the classic endophenotype hypothesis, 
which states that alleles associated with reduced cognitive ability should also serve to increase risk 
for schizophrenia. We tested the endophenotype hypothesis by applying polygenic SNP scores 
derived from a large-scale cognitive GWAS meta-analysis (~5000 individuals from 9 non-clinical 
cohorts comprising the COGENT consortium) to four schizophrenia case-control cohorts. As 
predicted, cases had significantly lower cognitive polygenic scores compared to controls. In 
parallel, polygenic risk scores for schizophrenia were associated with lower general cognitive 
ability. Additionally, using our large cognitive meta-analytic dataset, we identified nominally 
significant cognitive associations for several SNPs that have previously been robustly associated 
with schizophrenia susceptibility. Results provide molecular confirmation of the genetic overlap 
between schizophrenia and general cognitive ability, and may provide additional insight into 
pathophysiology of the disorder.
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INTRODUCTION
Schizophrenia (SCZ) is a brain disorder characterized by, on average, a reduction in general 
cognitive abilities of >1 SD below the population mean. Given the long-standing 
observation of subtle cognitive abnormalities in undiagnosed and unmedicated relatives of 
patients with SCZ, it has been suggested that cognitive deficits may serve as an 
endophenotype, permitting identification of SCZ risk genes using a quantitative phenotype 
more closely reflecting gene function.1 Extensive family and twin data support the role of 
shared additive genetic factors underpinning both SCZ and cognitive deficits.2 A recent 
population-scale study of siblings and twins further suggested that the overlap between these 
phenotypes is largely genetic, but questioned the overall magnitude of the phenotypic 
correlation.3 However, these family-based studies have two primary limitations: 1) they lack 
direct molecular assays of genetic variance, and 2) they have relied upon measurement of 
cognitive abilities in patients with SCZ, which are subject to potential confounds relating to 
illness process and state.
A direct test of the endophenotype hypothesis would examine molecular genetic variants 
associated with cognitive performance in the general (not clinically-referred) population, in 
order to see if these variants are also associated with SCZ. However, this approach has not 
been adequately tested due to the lack of strongly replicated cognition-associated single 
nucleotide polymorphisms (SNPs). By contrast, a number of candidate gene studies have 
applied a “reverse endophenotype” approach, in which SCZ risk variants are tested for 
association with cognition in the general population.4,5
Large-scale genome-wide association studies (GWAS) of schizophrenia have demonstrated 
that a substantial proportion of the heritability of the disorder is explained by a polygenic 
component consisting of thousands of common SNPs of extremely small effect.6 Similarly, 
recent GWAS of general cognitive ability have indicated that a polygenic architecture 
accounts for a majority of the heritability, consistent with other normally-distributed traits in 
the general population, such as height.7–9 The relationship of the underlying genetic 
architecture between two phenotypes can be examined using polygenic score tests, in which 
large numbers of alleles demonstrating subtle (not statistically significant) levels of 
association with a given phenotype are combined to produce a genetic risk profile.10 The 
association of these alleles in a different cohort (measured on a different phenotype), can 
then be utilized to estimate the degree of molecular overlap between phenotypes.
Very recently, two reverse endophenotype studies have examined the ability of 
schizophrenia polygenic risk scores to predict cognitive abilities in independent cohorts.11,12 
Both studies draw from the work of the Psychiatric GWAS Consortium on Schizophrenia 
(PGC-SCZ), a large-scale mega-analytic GWAS of 17 Caucasian cohorts encompassing 
>9000 SCZ cases and >12,000 controls.13 In one study12, polygenic risk scores for SCZ 
were significantly associated with IQ in a cohort of patients with SCZ and controls, but 
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these associations were not observed in the smaller (n=322) healthy cohort alone. However, 
in a much larger study11, polygenic risk scores for SCZ were found to be significantly 
associated with general cognitive ability (as assessed by the first principal component of 
cognitive tests assessing multiple domains) in two moderately-sized (total N~1500) cohorts 
of psychiatrically normal older adults.
In this study, we sought to test the endophenotype hypothesis by comparing SCZ cases to 
controls on polygenic SNP scores derived from a large-scale meta-analysis of cognitive 
GWAS. We focused on general cognitive ability as the primary endophenotype for several 
reasons, which we have discussed in detail previously.14 While a variety of specific 
cognitive traits have been proposed as SCZ endophenotypes, research to date has failed to 
conclusively demonstrate any specific cognitive signature of schizophrenia.15 Overall, 
deficits in general cognitive ability follow the pattern required of an endophenotype1: they 
are observed in SCZ patients prior to illness onset, are largely independent of clinical state 
and medication status, and are familial in nature.16,17
It has been recognized for more than 100 years that most cognitive abilities in humans are 
not orthogonal traits, but tend to covary; the underlying factor accounting for this pattern of 
intercorrelation is termed general cognitive ability (or Spearman’s g).18 General cognitive 
ability is a robust phenotype, accounting for nearly half of the variance on the broad range of 
specific neurocognitive traits identifiable in humans.19 Moreover, general cognitive ability 
in the population is itself highly heritable,9,20,21 and heritability studies have demonstrated 
substantial genetic overlap across most specific cognitive domains tested.18,19,21 Crucially, 
general cognitive ability can be reliably estimated by extracting the first principal 
component of any appropriately diverse set of neurocognitive test scores, regardless of the 
specific components of the battery; it has been empirically demonstrated that estimates of g 
derived from varying batteries tend to be very highly correlated, with correlation coefficients 
often approaching 1.22,23
The present study represents the first empirical report of an international collaborative effort 
entitled, “The Cognitive Genomics Consortium (COGENT).”14 COGENT aims to bring 
together human genetic datasets with both: 1) high-density genome-wide genotype data and 
2) phenotype data on cognitive function in individuals drawn from the general population. 
At the time of the first data freeze, COGENT consists of nine sites across 7 countries, with 
approximately 5000 individuals with available genotype and phenotype data. Although 
genotyping platforms and phenotype measures vary by site, genetic imputation and factor 
analysis of cognitive scores were used to harmonize data across sites. Because generalized 
cognitive ability (g) can be robustly estimated from a variety of test batteries, we were able 
to perform meta-analysis of GWAS associations to g across the nine COGENT cohorts. 
From this meta-analysis, we derived polygenic allele scores associated with general 
cognitive ability. These allele scores were then applied to four SCZ case-control cohorts 
consisting of more than 11,000 independently ascertained subjects (>5000 cases and >5000 
controls), as described in detail below. We additionally performed “reverse endophenotype” 
analyses, examining the effects of schizophrenia risk alleles (derived from PGC-SCZ) on 
cognitive scores in the 9 COGENT cohorts.
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MATERIALS AND METHODS
Subjects – Cognitive GWAS cohorts
Volunteers for cognitive studies were drawn from nine cohorts, for which study 
investigators agreed to share data as part of the Cognitive Genomics Consortium 
(COGENT). Details on subject recruitment procedures for each cohort are described in the 
Supplementary Materials; summaries of each cohort are presented in Table 1. Although 
screening procedures differed somewhat across cohorts, subjects were drawn from the 
general population, either as epidemiologically representative cohorts or as recruited control 
cohorts for studies of schizophrenia and/or other mental illnesses. All subjects were of 
Caucasian descent (as confirmed by principal components analysis of genetic data). All 
subjects provided written, informed consent to protocols approved by their institutional 
ethics boards in accordance with the Helsinki declaration.
Subjects – Schizophrenia case-control cohorts
The primary test of the endophenotype hypothesis was performed in the Molecular Genetics 
of Schizophrenia (MGS) European-American case-control cohort. This dataset was selected 
for several reasons: it is large (n>5000), publicly available, has been extensively 
studied,24–26 and contains an ethnic distribution that is comparable to our nine COGENT 
cohorts (primarily Northern European in ancestry but with a non-negligible Southern 
European component as well). To replicate and extend our findings, we secondarily tested 
three additional SCZ case-control cohorts of varying ethnicities: 1) A Japanese cohort with 
>1000 subjects;27 2) An Ashkenazi Jewish cohort with >2500 subjects;28 and the African-
American subcohort (n>2000) of the MGS sample.25 Demographic details of these cohorts 
are presented in Table 2. It should be noted that increasing evidence suggests substantial 
common architecture of complex traits (including schizophrenia) across populations,29,30 
but it would still be anticipated that replication samples would demonstrate attenuated effect 
sizes due to residual differences in allele frequencies and effect sizes.31
Genotyping, quality control, and imputation
As described in detail in the Supplementary Materials, all COGENT subjects were 
genotyped on one of three microarray platforms: Affymetrix 6.0 (~900K SNPs), Illumina 
610K, or Illumina OmniExpress (~770K SNPs). A standardized quality control pipeline was 
applied to each COGENT GWAS dataset: SNP call rate > 95%; sample call rate > 90%; 
SNP Hardy-Weinberg equilibrium (HWE) p>10−6; and X chromosome sex match with 
reported gender. For any pair of subjects with cryptic relatedness (pi-hat>.125 in PLINK32 
1.07), the sample with the lower call rate was eliminated. For each dataset, a principal 
components analysis was performed (in SVS 7.7.4, GoldenHelix Inc., Bozeman, MT), and 
samples demonstrating non- Caucasian ancestry were eliminated.
After QC, all SNPs within a given cohort were strand-aligned to HapMap3 and phased using 
SHAPEIT33 prior to imputation with IMPUTE2.34 As recently recommended to increase 
imputation accuracy,35 a large, cosmopolitan HapMap3 reference panel (n=1,011 
individuals from Africa, Asia, Europe, and the Americas) was utilized (except for NCNG, 
which was the only dataset for which imputation was not performed centrally). Because our 
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phenotype is a quantitative trait, we sought to avoid potentially spurious findings introduced 
by random association of rare alleles with a few extreme scores.36 Therefore, imputed SNPs 
receiving a probability call >.90 were retained and converted to PLINK-format genotype 
calls. The imputed data were then recleaned using the same call rate and HWE criteria 
described above; additionally, SNPs with minor allele frequency <2.5% were dropped. For 
each cohort, ~3000 randomly selected genotyped SNPs were held out for concordance 
analysis with imputation results. As shown in Table 1, concordance exceeded 99% for seven 
COGENT cohorts, and ~1M SNPs were available for analysis in each cohort.
Neurocognitive assessment
Details of neurocognitive batteries for each cohort are provided in the Supplementary 
Materials. While the specific instruments varied across cohorts, each cohort was required to 
have test scores available across at least 3 domains of cognitive ability for computation of 
Spearman’s g,18,37 an estimate of general cognitive ability derived from principal 
components analysis (PCA).22,23 (For one cohort, a validated estimate of general cognitive 
ability derived from two subscales of the Wechsler Adult Intelligence Scale was utilized.) 
For each of the cohorts, available measures were entered into PCA and the first unrotated 
component was extracted. Any variable with more than 5% of missing data was dropped 
from the analysis. Normality is not a strict requirement of principal components analysis 
implemented for the purpose of data reduction and so no variable was subject to 
transformation.38 Moreover, inspection of box plots indicated that variables were generally 
normally distributed and no noticeable outliers were observed. In each cohort, as expected 
based on hundreds of prior studies,39 the first principal component significantly loaded all 
measures and accounted for ~40% of the variance on average.
The dependent measure for the cognitive GWAS in each cohort was this first PC score, 
corrected for the following (using linear regression prior to GWAS): age, sex, age*sex, age2, 
and age2*sex, based on consistent evidence demonstrating the presence of both linear and 
quadratic effects of age on general cognitive ability across the lifespan40.
Statistical analysis
Genome-wide association analysis of the quantitative cognitive phenotype was performed in 
each COGENT cohort using linear regression (additive model) in SVS7.7.4. As shown in 
Table 1, lambda (genomic control) values for each cohort were at or near 1, indicating no 
significant effect of subtle population structure on association results. Fixed effects meta-
analysis of β weights from the linear regression analyses was performed in PLINK 1.0732 
using data from all available cohorts possessing high-QC genotyped or imputed data for 
each given SNP. Only SNPs with data available in 3 or more cohorts were retained. By 
convention, a positive β weight for a given allele indicated an additive (allele-dose) 
relationship in the direction of higher cognitive phenotype scores.
Based on results of the meta-analysis, polygenic scores were computed in PLINK using β 
weights of alleles at varying statistical thresholds (nominal p<.10, .20, .30, .40, and .50) 
following the procedure originally described by Purcell et al.10 For each statistical threshold, 
the clump procedure in PLINK was utilized to prune the set of SNPs for linkage 
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disequilibrium (using r2 threshold of .50 within a 250kb window), so as to avoid redundancy 
of SNPs representing a given association signal.
For each of the five statistical thresholds, the weighted allele scores of each “clumped” SNP 
were summed for each subject in each SCZ case-control cohort, thus creating a “cognitive 
polygene score.” Thus, each subject in each SCZ case-control dataset had a set of 5 
cognitive polygene scores: one for each of the statistical thresholds applied to the original 
COGENT meta-analytic results. For each SCZ case-control dataset, five logistic regression 
analyses were then used to compare cases and controls on cognitive polygene scores at each 
threshold. Nagelkerkes’ pseudoR2 was utilized to reflect estimated percent variance in the 
SCZ phenotype accounted for by cognitive polygene scores at each threshold.10
RESULTS
GWAS results for general cognitive ability
Meta-analytic results of the nine cognitive GWAS cohorts are presented as a Manhattan plot 
in Figure 1; no SNPs reached genomewide significance, and the overall lambda was 1.031 
(see QQ plot in Supplementary Figure 1). This lambda value is higher than that for any 
individual cohort (Table 1), indicative of polygenic signal41, but is lower than reported in 
similar recent studies of cognitive ability7,9. A list of top SNPs (p<.001) emerging from the 
meta-analysis are presented in Supplementary Table 1.
Primary test of endophenotype hypothesis – cognitive polygenic score analysis
We utilized a large, publicly available, Caucasian SCZ GWAS case-control cohort to test 
our primary endophenotype hypothesis. Using “clumped” SNPs at 5 different thresholds 
(nominal p<.10, .20, .30, .40, and .50), polygenic cognitive scores were computed for each 
of 2886 cases and 2056 controls in the MGS/GAIN European-American cohort. As 
predicted, cases had significantly lower cognitive polygenic scores across each of the five 
thresholds (p-values ranging from 6.56*10−6 to 3.73*10−7; see Figure 2). In other words, 
SCZ cases had fewer alleles associated with good cognitive performance and more alleles 
associated with poorer cognitive performance in the COGENT meta-analysis. The overall 
magnitude of the polygenic effect was small (R2<.01), but comparable to the total variance 
explained by a similar approach applied from one cognitive cohort to another7 and from a 
reverse endophenotype study.11
As replication, the same cognitive SNPs were tested in three smaller SCZ case-control 
cohorts of differing ethnicities. Because of the apparent dip in variance explained that 
appears at p<0.2 in the MGS EA cohort (Figure 1), we applied a p<0.3 threshold in our 
replication datasets. As depicted in Table 3, nominally significant results were observed in 
two cohorts (Japanese and Ashkenazi Jewish). Meta-analysis of these results across the four 
SCZ case-control cohorts yielded a strongly significant effect of cognitive polygenic scores 
on prediction of schizophrenia risk (p=3.6*10−7). Very similar results were observed using a 
clump threshold of p<0.5 (Supplementary Table 2; meta-analytic p=3.8*10−7), and 
somewhat stronger results were observed when the IBG cohort (the only non-adult 
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COGENT cohort) was removed prior to calculation of polygenic allele weights 
(Supplementary Table 3; meta-analytic p=4.0*10−9).
Reverse endophenotype approach – examination of prior schizophrenia GWAS hits
As an additional examination of the relationship between cognitive GWAS results and the 
schizophrenia phenotype, we applied the commonly-employed “reverse endophenotype” 
approach described above. First, we selected all SNPs that have demonstrated genomewide 
significance (p<5*10−8) in large-scale (total n>5000) published SCZ GWAS obtained from 
the NHGRI GWAS catalog (http://www.genome.gov/gwastudies/, downloaded Jan. 10, 
2013). As shown in Table 4, four of the 13 independent SNPs (excluding the major 
histocompatibility complex) associated with schizophrenia have nominally significant (p<.
05) associations with general cognitive ability in volunteers from the general population. 
While effect sizes for these SNPs on cognitive phenotypes are extremely modest, the 
number of SNPs achieving nominal significance exceeded that expected by chance 
(binomial test, p=.006, two-tailed). Although extensive linkage disequilibrium in the MHC 
has prohibited clear discernment of the source of SCZ GWAS signal, supplementary Table 4 
demonstrates results for 5 SNPs in the region derived from published SCZ GWAS.
Reverse endophenotype approach – schizophrenia susceptibility polygenic score analysis
Finally, we performed a polygenic score analysis, comparable to the one presented in Table 
2, but in the “reverse” direction. Specifically, we downloaded “clumped” SNPs derived from 
the publicly-available PGC13 dataset (https://pgc.unc.edu/Sharing.php#SharingOpp). 
Because polygenic score approaches to schizophrenia have tended to demonstrate increasing 
variance explained at higher p-value thresholds10, we utilized a threshold of p<.50 on the 
resulting clumped SNPs. These polygenic scores were then computed for each subject in 
each of the 9 COGENT cohorts separately; scores were then compared to cognitive ability 
(g) using linear regression in each cohort. As shown in Table 5, schizophrenia-derived 
polygenic scores were correlated with cognitive ability in the predicted direction (greater 
schizophrenia load associated with lower cognitive scores) in 7 of the 9 cohorts, with three 
cohorts demonstrating nominally significant (or nearly so) results. As with the primary 
analysis, total variance accounted for was small (R2 range from 0–2%) but strongly 
significant (p=1.4*10−4) in the combined analysis.
DISCUSSION
To our knowledge, this is the first study to present molecular genetic evidence supporting 
general cognitive ability as a true endophenotype for schizophrenia susceptibility. In a large 
Caucasian SCZ case-control cohort, we demonstrated that a set of polygenic alleles 
associated with lower general cognitive ability strongly predicted increased likelihood for 
the disorder. Consistent, though less strong, associations were observed in additional 
cohorts, despite the fact that they were drawn from populations of differing ethnicities.
While the statistical evidence (p-values ranging from ~10−6 to ~10−9) for association was 
strong, the overall amount of variance explained, even in the Caucasian SCZ cohort (~0.5%) 
was modest, a result that must be interpreted in the context of other studies of polygenic 
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overlap. For example, in a recent study of cognition,7 polygenic SNP scores accounted for 
only ~1% of the variance in a separate cognitive cohort (these cohorts are now included in 
COGENT). Nevertheless, these authors were able to demonstrate that nearly half of the 
variation in cognitive ability could ultimately be accounted for by common SNPs. Similarly, 
the initial study of polygenic effects in schizophrenia identified only ~2–3% overlap 
between any two schizophrenia cohorts, and ~1–2% overlap between schizophrenia and 
bipolar cohorts.10 Again, extensive simulations demonstrated that the polygenic SNPs 
tagged common genetic variation accounting for approximately one-third of the total 
variance in SCZ risk; this estimate has been replicated, indicating that the empirically 
observed cross-sample allelic overlap is a substantial under-estimate of the total polygenic 
effect.6 Moreover, observed polygenic overlap tends to rapidly increase as a function of 
sample size; for example, the empirically observed variance explained by polygenic effects 
in schizophrenia has increased tenfold with larger sample sizes.42 While the COGENT 
cohort represents the largest genetic sample of cognition to date, sample size remains small 
relative to polygenic studies of other quantitative traits such as height.43,44
Thus, the results of the present study are consistent with a model in which a substantial 
fraction of the molecular basis of general cognitive ability is shared with genetic risk for 
schizophrenia. These results are consistent with a large body of evidence from family-based 
studies which use twin and sibling correlations to model genetic effects.2 While a recent 
population-based study using similar modeling strategies3 found only limited phenotypic 
overlap between intelligence and psychosis, the source of this overlap was estimated to be 
largely (~90%) comprised of additive genetic variation. The present study is unique in 
directly testing molecular genetic variation, and utilizing non-clinical volunteers for the 
estimation of the cognitive genetic component. Our demonstration of parallel effects when 
examining genomewide overlap in the reverse direction (SCZ risk alleles predicting 
cognitive scores, Table 5) add further confidence to our conclusions, and are also consistent 
with a recent genomewide reverse endophenotype study, which demonstrated significant 
overlap between polygenic SCZ risk alleles and cognitive decline in two aging cohorts.11
Additionally, following the conventional “reverse endophenotype” approach, multiple 
GWAS-identified SCZ risk SNPs (4/13, or 31%) demonstrated nominal evidence of 
association to general cognitive ability in a large meta-analytic cohort of non-clinical 
volunteers. Three of these are intronic SNPs, in MAD1LI, LSM1, and CNNM2, and the 
present study represents the first report of human neurocognitive correlates of variants at 
these loci. Little is known about the functions of these genes in the central nervous system, 
and the structural and functional properties of their associated proteins vary widely. The 
fourth nominally significant locus is less than 5kb 5’ to NRGN (and is in an LD block 
encompassing the gene). NRGN encodes neurogranin, a well-characterized postsynaptic 
protein which binds to calmodulin and thereby modulates postsynaptic calcium signaling.45 
Although this locus did not show significant association with cognitive variables in a smaller 
prior study,46 neuroimaging studies have previously associated this locus with structural and 
functional variation in the frontal cortex, cingulate, and hippocampus.47–50 Although these 
results were significant in the aggregate (p=.006 by binomial test), it should be emphasized 
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that the effect sizes for individual SNPs were extremely small, and p-values would not 
survive Bonferroni correction.
Based on the present results, it is likely that larger sample sizes will afford greater ability to 
predict schizophrenia using cognitive polygenic scores. This overlap can then be utilized to 
enhance schizophrenia gene detection using recently developed “pleiotropic enrichment” 
techniques.51 At the same time, the study of the genetic basis of normal variation in 
cognition is likely to further our understanding of the mechanisms by which schizophrenia 
risk genes affect the central nervous system.
Several caveats should be placed on the interpretation of this study. First, the present study 
did not directly evaluate the genetic source of cognitive deficits in patients with 
schizophrenia. It could be argued that GWAS of cognitive ability in schizophrenia cohorts 
would be required to test whether this putative endophenotype actually mediates the 
relationship between cognitive polygene score and schizophrenia risk. However, cognitive 
performance in patients with schizophrenia can be influenced by potential confounds such as 
effects of medication or acute symptomatology, which would tend to attenuate any genetic 
signal. Consequently, our approach of utilizing non-clinical samples was designed to 
maximize the potential power of GWAS.
Finally, it should be noted that no genomewide significant loci for cognition were identified 
in the present study, despite being the largest GWAS of cognitive ability in predominately 
adult cohorts. This result was anticipated based on recent large-scale GWAS results for 
childhood intelligence9, as well as early GWAS (with comparable sample size to the present 
study) of potentially comparable quantitative traits, height52 and weight53. It is also possible 
that power to detect genetic signals was reduced due to unavoidable heterogeneity in 
cognitive assessment methods across cohorts; such an interpretation is consistent with the 
relatively low lambda observed in our study. Future studies, ideally with prospectively 
collected cohorts utilizing harmonized approaches to phenotype assessment, will be required 
to tease out genomewide significant loci for cognitive ability.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Manhattan plot depicting results of COGENT meta-analysis.
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Figure 2. 
Polygenic overlap between cognitive allele scores (derived from COGENT metaanalysis 
thresholded at varying p-values) and schizophrenia (SCZ) case-control status in the MGS 
European-American cohort.
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Table 1
Description of COGENT cohorts.
Dataseta Genotyping
Platform
Concordanceb Genotypes
after QC
N %Male Mean Age (SD) Lambdac
Germany Illumina OE d 99.50% 1,078,289 594 51% 54.0 (15.0) 1.01
LOGOS Illumina OE 99.40% 835,287 802 100% 22.3 (3.8) 1.03
IBG Affymetrix 6.0 99.59% 938,800 299 77% 15.9 (1.5) 1.00
LBC1936 Illumina 610 99.60% 1,058,722 1005 51% 69.5 (0.8) 1.01
TOP Affymetrix 6.0 94.23% 917,315 351 48% 34.2 (9.8) 1.01
NCNG Illumina 610 99.40% 944,135 629 32% 47.6 (18.3) 1.00
Manchester Illumina 610 99.60% 1,059,916 697 30% 67.7 (2.8) 1.01
HBCS Illumina 610 99.60% 1,043,380 318 100% 67.7 (2.3) 1.00
ZHH Illumina OE 99.40% 1,043,785 201 47% 39.1 (1.8) 1.06
a
Detailed descriptions of each cohort provided in Supplementary Text.
bConcordance between imputed and genotyped SNPs.
c
Lambda to refers λGC,, a measure of the degree of statistical inflation in genomewide association studies.
dOE refers to the Illumina OmniExpress genotyping bead chip
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Table 2
Description of schizophrenia case-control cohorts.
SCZ Dataset N Cases N Controls GWAS platform
MGS European-American Shi et al. 2009 2681 2653 Affymetrix 6.0
Japan Ikeda et al. 2011 575 564 Affymetrix 5.0
Ashkenazi Jewish (Israel) Guha et al. 2013 904 1640 Illumina Omni1-Quad
MGS African-American Shi et al. 2009 1286 973 Affymetrix 6.0
Total 5446 5830
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Table 3
Polygenic overlap between cognitive alleles (derived from COGENT meta-analysis using p<0.3 threshold) 
and schizophrenia in four case-control cohorts.
SCZ Dataset # overlapping SNPs R2 for SCZ p value direction
MGS European-American 17,237 0.41% 1.3*10−6 negative
Japan 6,468 0.38% 0.039 negative
Ashkenazi Jewish 15,151 0.16% 0.041 negative
MGS African-American 17,382 0.00% 0.958 positive
Meta-analysis 3.6*10−7 negative
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Table 5
Polygenic overlap between schizophrenia risk alleles (derived from PGC meta-analysis using p<0.5 threshold) 
and general cognitive ability in nine COGENT cohorts.
COGENT Dataset # overlapping
SNPs
R2 for g p value Direction
Germany 89,360 0.08% 0.475 Positive
LOGOS 69,069 0.00% 0.985 Positive
IBG 89,353 0.04% 0.72 Negative
LBC1936 96,820 1.17% 0.0006 Negative
TOP 88,946 0.10% 0.5481 Negative
NCNG 87,934 0.04% 0.5925 Negative
Manchester 96,907 1.61% 0.0007 Negative
HBSC 93,890 0.11% 0.5467 Negative
ZHH 85,681 1.90% 0.0532 Negative
Meta-analysis 1.4*10−4 negative
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